Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
331.4 GBX | -0.03% | +1.72% | +3.03% |
Apr. 25 | Moody’s Affirms Haleon’s Ratings on Strong Operating Performance | MT |
Apr. 24 | Haleon: a new CFO at the end of October | CF |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in debt and has limited leeway for investment
- The company's enterprise value to sales, at 3.33 times its current sales, is high.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.03% | 37.83B | B | ||
+24.35% | 653B | C+ | ||
+25.80% | 556B | B | ||
-6.33% | 354B | C+ | ||
+19.90% | 331B | B- | ||
+7.95% | 296B | C+ | ||
+12.81% | 233B | B+ | ||
+5.07% | 201B | B- | ||
-10.02% | 193B | A+ | ||
-6.47% | 144B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLN Stock
- Ratings Haleon plc